Pharmacokinetics, distribution, metabolism, excretion and safety characterization of ZJCK-6-72: novel DYRK1A inhibitor with optimized brain exposure for Alzheimer’s disease therapy
Artículo
Material complementario disponible
Artículo
DOAJ
Developing effective drugs for Alzheimer’s Disease (AD) is critically limited by insufficient brain exposure. To address this, structural optimization was employed to balance physicochemical properties and enhance bloo...
LCC LCC:Therapeutics. PharmacologyIdioma eng
Material complementario disponibleEl enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Material complementario